Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma.

Using a random number table method, 124 nasopharyngeal carcinoma patients who received radiotherapy in the hospital from January 2020 to December 2021 were randomly divided into a control group of 62 cases and an experimental group of 62 cases. The control group received routine nursing care. Based on the control group, the experimental group used Tuhuanglian liquid wet compress from the beginning to the end of radiotherapy. The severity of acute radiation dermatitis in two groups of patients is observed at different radiotherapy times. At the end of the 10th radiotherapy, there was no statistically significant difference in radiation therapy oncology group (RTOG) grading between the two groups of patients (P > 0.05). At the end of the 20th radiotherapy and the end of radiotherapy, there was a statistically significant difference in RTOG grading between the two groups of patients (P < 0.05). The time for patients in the experimental group to develop radiation grade 3 dermatitis was longer than that in the control group, with a median time of 9 days, and the difference was statistically significant (P < 0.05). Therefore, Tuhuanglian wet compress therapy can reduce the incidence of acute radiation dermatitis in nasopharyngeal carcinoma patients, delay the progression of acute radiation dermatitis, and can be widely used.